Article Figures & Data
Tables
Ecstasy (MDMA) use disorder (Years) Mean±SD Age 27.40±6.96 Age of onset 16.84±4.21 Duration of disorder 11.29±7.46 Sex n (%) Female 0 (0) Male 82 (100) Education Literate 4 (4.9) Primary School 18 (22.0) Secondary School 40 (48.8) High School 19 (23.2) University 1 (1.2) COMT Val158Met Met/Met 12 (14.6) Val/Met 34 (41.5) Val/Val 36 (43.9) Tobacco - No 1 (1.2) Usage - Yes 81 (98.8) Alcohol - No 50 (61) Usage - Yes 32 (39) Psychotic - No 37 (45.1) Symptom - Yes 45 (54.9) Attempted - No 56 (68.3) Suicide - Yes 26 (31.7) SD - standard deviation, MDMA - 3,4-Methylenedioxymethamphetamine, COMT - Catechol-O-methyltransferase
- Table 2
- Comparison of genotype distributions of COMT Val158Met polymorphism in patients with the control.
Genotype MDMA Control OR 95% CI P-value COMTVal158Met n=a (%) n=95 (%) Met/Met 12 (14.6) 30 (31.6) 2.692* 1.272-5.698* 0.008* Val/Met 34 (41.5) 32 (33.7) 0.717* 0.389-1.322* 0.286* Val/Val 36 (43.9) 33 (34.7) 0.680* 0.371-1.248* 0.212* Allele Met 58 (35.4) 92 (48.4) Val 106 (64.6) 98 (51.6) 1.716* 1.118-2.633* 0.013* MDMA, 3,4-Methylenedioxymethamphetamine; an= 82; OR, odds ratio; CI, confidence interval; *Pearson chi-square
- Table 3
- Comparison of genotype distributions of COMT Val158Met in patients due to psychotic symptoms.
Psychotic Symptoms/Genotype Yes No OR 95% CI P-value COMTVal158Met n= a (%) n=37 (%) Met/Met 5 (11.1) 7 (18.9) 0.536* 0.155-1.854* 0.320* Val/Met 25 (55.6) 9 (24.3) 3.889* 1.498-10.094* 0.004* Val/Val 15 (33.3) 21 (56.8) 2.625* 1.069-6.446* 0.033* Allele Met 35 (38.9) 23 (31.1) Val 55 (61.1) 51 (68.9) 1.411* 0.737-2.702* 0.298* COMT, Catechol-O-methyltransferase; an= 45; OR, odds ratio; CI, confidence interval; *Pearson chi-square
In this issue
COMTVal158Met polymorphism is associated with ecstasy (MDMA)-induced psychotic symptoms in the Turkish population
Jump to section
Related Articles
Cited By...
- No citing articles found.